Medicines, 2021
Shortlist up to four to read them side by side.
1,016 medicine recalls FDA’s Enforcement Report published in 2021, newest first; 18,075 in all since 2012.
FDA’s medicine recalls, as its Enforcement Report classifies them, from June 2012. Lists of FDA’s records can’t be saved for alerts: openFDA asks that its data not be used to alert the public (openFDA); FDA’s own emails do that. Copied Nov 5, 2026.
1,016of 1,016 medicine recallsshown with your filters
The list
- Medicine recall MIC 20/40/50 /B COMPLEX +CHROM/CARN 25/25MG/ML 20/40/50/25/25MG/ML INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall MIC 20/40/50 /B COMPLEX +CHROM/CARN 25/25MG/ML+LIDO 20/40/50/25/25MG/ML+LIDO INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall MIC B COMPLEX INJ-MILES FORMULATION INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall MIC B COMPLEX W CHROMIUM/ METHYLCOB (BOYDEN) INJ INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall MIC B COMPLEX WITH HYDROXOCOBALAMIN 5MG/ML INJ INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall MIC B12 25/50/50/0.5MG/ML L-CARNITINE 250MG/ML INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall MIC B12 25/50/50/1+B6 100 MG/ML INJ INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall PROGESTERONE 100MG/ML INJ #1 IN ETHYL OLEATE INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall QUAD-MIX PAPAV 20/PHENTOL 2/PGE-1 25/ATROPINE 0.2 INJ INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall QUAD-MIX PAPAV 30/PHENTOL 1/PGE-1 10/ATROPINE 0.15 INJ INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall QUAD-MIX PAPAV 30/PHENTOL 1/PGE-1 20/ATROPINE 0.1 INJ INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall QUAD-MIX PAPAV 30/PHENTOL 2/PGE-1 20/ATROPINE 0.2 INJ *C5* INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall QUAD-MIX PAPAV 30/PHENTOL 2/PGE-1 200/ATROPINE 0.02 INJ INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall QUAD-MIX PAPAV 30/PHENTOL 2/PGE-1 30/ATROPINE 0.2 INJ INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall QUAD-MIX PAPAV 30/PHENTOL 3/PGE-1 100/ATROPINE 0.2 INJ INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall QUAD-MIX PAPAV 30/PHENTOL 4/PGE-1 40/ATROPINE 0.4 INJ *C6* INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall SERMORELIN ACETATE 15MG/IPAMORELIN 15MG - LYOPHILIZED 15MG/15MG VIAL Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall SERMORELIN ACETATE 6MG/IPAMORELIN 6MG - LYOPHILIZED 6MG/6MG VIAL Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall SERMORELIN ACETATE 9MG/IPAMORELIN 9MG - LYOPHILIZED 9MG/9MG VIAL Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TRIMTROPIC - MIC B COMPLEX/CHROM/CARN 20MG/40MG/50MG/5MG/33MG/2MG/1MG/25MCG/25MG INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TRI-TEST 200 (CY50%-EN37.5%-PR12.5%) INJ #1 200MG/ML INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall ULTRA-TEST (CYP 80%/PROP 20%) 200MG/ML INJ #1 200MG/ML INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall VITAMIN D3 100,000 IU/ML INJECTABLE 100,000IU/ML Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 0.25MG/DUTASTERIDE 1MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 0.5MG/DUTASTERIDE 0.5MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 0.5MG/DUTASTERIDE 0.75MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 0.5MG/DUTASTERIDE 1.5MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 0.5MG/DUTASTERIDE 1MG/ML #2 INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 0.5MG/DUTASTERIDE 1MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 0.75MG/DUTASTERIDE 1MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 1.5MG/DUTASTERIDE 1.5MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 1.5MG/DUTASTERIDE 2MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 1MG/DUTASTERIDE 0.5MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 1MG/DUTASTERIDE 1.5MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 1MG/DUTASTERIDE 1MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 1MG/DUTASTERIDE 2MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 2MG/DUTASTERIDE 0.5MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/ANASTROZOLE 2MG/DUTASTERIDE 2MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/DUTASTERIDE 0.5MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/DUTASTERIDE 1MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TEST CYPIONATE 200MG/DUTASTERIDE 2MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TESTOSTERONE BI-BLEND 100/100MG/ML INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TESTOSTERONE CYPIONATE 100MG/ML INJ #1 IN ETHYL OLEATE INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TESTOSTERONE CYPIONATE 200MG/ANASTROZOLE 0.25MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TESTOSTERONE CYPIONATE 200MG/ANASTROZOLE 0.5MG/ML INJ #1 IN ETHYL OLEATE INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TESTOSTERONE CYPIONATE 200MG/ANASTROZOLE 0.5MG/ML INJ #2 IN SESAME OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TESTOSTERONE CYPIONATE 200MG/ANASTROZOLE 0.75MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
- Medicine recall TESTOSTERONE CYPIONATE 200MG/ANASTROZOLE 0.7MG/ML IN OIL INJECTABLE Lack of assurance of sterility Class IIFDA’s classNov 17, 2021in FDA’s Enforcement Report2 statesnamed in where it went PublishedNov 17, 2021ClassClass IIStatusTerminatedWhereDistrict of Columbia and Puerto Rico
Nothing matches all of these.
Remove a filter to see more. Each one is a fact FDA’s record publishes, so a recall can be left out because its record is silent on it.
Source:
FDA, Drug recall enforcement reports. Released Nov 3, 2026. Updated weekly.
Recalls of food, medicines, medical devices, pet food and animal drugs are from the U.S. Food and Drug Administration (FDA). FDA does not endorse Hearth Record. openFDA: “Do not rely on openFDA to make decisions regarding medical care.”
Your shortlist0 of 4
Add one more to compare.